Jagsonpal Pharmaceuticals Share Price
28 Oct, 2026 3:52 PM (IST)
Jagsonpal Pharmaceuticals Performance
- Today's Low
- ₹222
- Today's High
- ₹239
- 52 Week Low
- ₹155
- 52 Week High
- ₹265
- Open Price₹225
- Previous Close₹223
- Volume118,982
- 50 DMA₹227.50
- 100 DMA₹224.60
- 200 DMA₹218.60
Jagsonpal Pharmaceuticals Chart
Investment Returns
- Over 1 Month -4.68%
- Over 3 Month + 0.59%
- Over 6 Month + 13.4%
- Over 1 Year + 7.1%
Smart Investing Starts Here Start SIP with Jagsonpal Pharmaceuticals for Steady Growth!
Jagsonpal Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 33.5
- PEG Ratio
- -1.3
- Market Cap Cr
- 1,523
- P/B Ratio
- 5.3
- Average True Range
- 9.9
- EPS
- 6.9
- Dividend Yield
- 1.7
- MACD Signal
- -3
- RSI
- 55.62
- MFI
- 25.5
Latest Stock News Updates
Press Release for Unaudited Financial Results for the quarter September 30, 2026
- BSE India
- 3 hours 43 minutes ago
Press Release for Unaudited Financial Results for the quarter ended September 30, 2026.
- BSE India
- 3 hours 50 minutes ago
<h3><span style="font-size:16px;"><strong>Pharmaceuticals company Jagsonpal Pharmaceuticals announced Q2FY27 results</strong></span><br /> <!--TgQPHd|||[[2,[null,null,null,null,null,null,null,null,null,null,null,null,[351768,null,0]],[],null,1]]--></h3> <p><!--TgQPHd|||[]--></p> <p><strong>Standalone Financial Highlights:</strong><!--TgQPHd|||[]--></p> <ul data-complete="true" data-hveid="CAAICRAA" data-processed="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="wiLEJc#NS0kde" jsuid="r8xNne_1r"> <li data-complete="true" data-hveid="CAAICRAC" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="r8xNne_1u"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="r8xNne_1w">Revenue from operations:<!--TgQPHd|||[]--></strong> For Q2FY27, stood at Rs 813.75 million, showing a QoQ decline of 1.04% compared to Rs 822.32 million in Q1FY27, but a YoY growth of 9.28% compared to Rs 744.65 million in Q2FY26. For H1FY27, it reached Rs 1,636.07 million, up 9.02% YoY against Rs 1,500.77 million in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAICRAF" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="r8xNne_23"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="r8xNne_25">Total income:<!--TgQPHd|||[]--></strong> For Q2FY27, stood at Rs 836.06 million, down 1.72% QoQ from Rs 850.65 million in Q1FY27, and up 7.89% YoY from Rs 774.92 million in Q2FY26. For H1FY27, it was Rs 1,686.71 million, registering a YoY increase of 8.17% compared to Rs 1,559.29 million in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAICRAI" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="r8xNne_2c"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="r8xNne_2e">Profit before tax (PBT):<!--TgQPHd|||[]--></strong> For Q2FY27, was Rs 168.28 million, representing a QoQ drop of 4.82% from Rs 176.80 million in Q1FY27, and a slight YoY increase of 0.11% from Rs 168.10 million in Q2FY26. For H1FY27, it stood at Rs 345.08 million, gaining 10.46% YoY from Rs 312.41 million in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAICRAL" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="r8xNne_2l"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="r8xNne_2n">Net profit after tax (PAT):<!--TgQPHd|||[]--></strong> For Q2FY27, was Rs 125.90 million, a decline of 4.54% QoQ from Rs 131.89 million in Q1FY27, and a marginal increase of 0.13% YoY compared to Rs 125.74 million in Q2FY26. For H1FY27, PAT stood at Rs 257.79 million, growing 10.31% YoY from Rs 233.69 million in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAICRAO" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="r8xNne_2u"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="r8xNne_2w">Earnings per share (EPS):<!--TgQPHd|||[]--></strong> Basic EPS for Q2FY27 was Rs 1.91 (down 4.50% QoQ and up 1.60% YoY). For H1FY27, basic EPS was Rs 3.91, up 11.71% YoY from Rs 3.50 in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAICRAR" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="r8xNne_33"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="r8xNne_35">Interest Earned:<!--TgQPHd|||[]--></strong> Not separately listed as a main line item under income in the statement of results, but Interest Income inside the cash flow adjustments stood at Rs 50.01 million for H1FY27 compared to Rs 56.99 million for H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <!--TgQPHd|||[]--> </ul> <p><!--TgQPHd|||[]--></p> <p><strong>Consolidated Financial Highlights:</strong><!--TgQPHd|||[]--></p> <ul data-complete="true" data-hveid="CAAICxAA" data-processed="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="wiLEJc#NS0kde" jsuid="r8xNne_3l"> <li data-complete="true" data-hveid="CAAICxAC" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="r8xNne_3o"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="r8xNne_3q">Revenue from operations:<!--TgQPHd|||[]--></strong> Stood at Rs 963.71 million for Q2FY27 and Rs 1,786.03 million for H1FY27.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAICxAD" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="r8xNne_3s"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="r8xNne_3u">Total income:<!--TgQPHd|||[]--></strong> Stood at Rs 986.22 million for Q2FY27 and Rs 1,836.87 million for H1FY27.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAICxAE" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="r8xNne_3w"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="r8xNne_3y">Profit before tax (PBT):<!--TgQPHd|||[]--></strong> Recorded at Rs 164.19 million for Q2FY27 and Rs 340.99 million for H1FY27.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAICxAF" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="r8xNne_40"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="r8xNne_42">Net profit after tax (PAT):<!--TgQPHd|||[]--></strong> Stood at Rs 122.87 million for Q2FY27 and Rs 254.76 million for H1FY27.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAICxAG" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="r8xNne_44"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="r8xNne_46">Earnings per share (EPS):<!--TgQPHd|||[]--></strong> Basic EPS stood at Rs 1.86 for Q2FY27 and Rs 3.86 for H1FY27.</li> </ul> <p><a class="lb" href="/get-document/post/pdf/5915175/" target="_blank">Result PDF</a></p>
- Trendlyne
- 3 hours 58 minutes ago
Jagsonpal Pharmaceuticals Financials
Jagsonpal Pharmaceuticals Technicals
EMA & SMA
- Bearish Moving Average 1
- Bullish Moving Average 15
- 20 Day
- ₹224.40
- 50 Day
- ₹227.50
- 100 Day
- ₹224.60
- 200 Day
- ₹218.60
Resistance and Support
- R3 256.30
- R2 247.70
- R1 239.30
- S1 222.30
- S2 213.70
- S3 205.30
Jagsonpal Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends
About Jagsonpal Pharmaceuticals
Jagsonpal Pharmaceuticals is engaged in the business of manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients. View More- NSE Symbol
- JAGSNPHARM
- BSE Symbol
- 507789
- ISIN
- INE048B01035
Similar Stocks to Jagsonpal Pharmaceuticals
Popular Stocks
Jagsonpal Pharmaceuticals FAQs
Jagsonpal Pharmaceuticals share price is ₹230 As on 28 October, 2026 | 22:17
The Market Cap of Jagsonpal Pharmaceuticals is ₹1523.4 Cr As on 28 October, 2026 | 22:17
The P/E ratio of Jagsonpal Pharmaceuticals is 33.5 As on 28 October, 2026 | 22:17
The PB ratio of Jagsonpal Pharmaceuticals is 5.3 As on 28 October, 2026 | 22:17
The 52 week High & Low of Jagsonpal Pharmaceuticals is ₹264.5/₹155 respectively As on 28 October, 2026 | 22:17
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.